A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
NCT ID: NCT00055419
Last Updated: 2010-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
744 participants
INTERVENTIONAL
2003-02-28
2004-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cetuximab in Treating Patients With Stage IV Colorectal Cancer
NCT00020930
Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma
NCT00725400
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
NCT00362102
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
NCT05985954
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
NCT00466505
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
400 mg/m2
Cetuximab
400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cetuximab
400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with histologically or pathologically confirmed metastatic colorectal cancer, which is EGFR-positive by IHC (may be based on archival samples)
* Subjects with ECOG performance status 0, 1 or 2.
* Subjects who have failed, either due to lack of efficacy or due to intolerance, all available chemotherapy for the treatment of metastatic colorectal cancer.
* Subjects who have failed to meet eligibility criteria for any other existing cetuximab trial.
* Subjects must have received at least two chemotherapy regimens for metastatic disease OR adjuvant therapy plus one chemotherapy regimen for metastatic disease, provided the subject progressed within 6 months of completing their adjuvant therapy.
* Prior chemotherapy must have included all of the follow drugs: irinotecan, oxaliplatin, and a fluoropyrimidine.
* Subjects adequately recovered from any recent surgery, radiation therapy or chemotherapy.
* Subjects accessible for treatment and follow-up. Subjects enrolled in this trial must be treated at the participating center.
* Subjects greater or equal to 18 years of age.
* Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks afterwards.
Exclusion Criteria
* Women who are pregnant or breastfeeding.
* Women with a positive pregnancy test on enrollment or prior to study drug administration.
* Sexually active, fertile men not using adequate birth control.
* Subjects with dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
* Subjects with a serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy.
* Subjects with a history of uncontrolled angina, arrhythmias, congestive heart failure, or myocardial infarction within the previous 6 months.
* Subjects with any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. Subjects with a previous malignancy but without evidence of disease for \> 5 years will be allowed to enter the trial.
* Subjects with any history of severe hypersensitivity reactions and/or anaphylaxis resulting from the administration of protein based therapeutic agents.
* Subjects with inadequate hematologic function defined by an absolute neutrophil count (ANC) \<1,250/mm3, a platelet count \<75,000/mm3, and a hemoglobin level \<8 g/dL.
* Subjects with inadequate hepatic function, defined by a total bilirubin level ³3 times the upper limit of normal (ULN) and an aspartate transaminase (AST) and alanine transaminase (ALT) levels \>5 x ULN.
* Subjects with inadequate renal function defined by a serum creatinine level \>2.5 x ULN.
* Prior cetuximab therapy, prior randomization on a study which includes cetuximab therapy in a treatment arm, or any other prior therapy that targets the EGFR pathway.
* A history of prior therapy with a chimerized or murine monoclonal antibody.
* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
* A history of cetuximab or therapy that targeted the EGFR receptor.
* A history of prior anti-cancer murine monoclonal antibody therapy.
* Additional concurrent chemotherapy or other investigational anticancer agents may not be administered to subjects on this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ImClone LLC
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
E-mail: ClinicalTrials@ ImClone.com
Role: STUDY_CHAIR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ImClone Investigational Site
Bakersfield, California, United States
ImClone Investigational Site
Los Angeles, California, United States
ImClone Investigational Site
Denver, Colorado, United States
ImClone Investigational Site
Torrington, Connecticut, United States
ImClone Investigational Site
Washington D.C., District of Columbia, United States
ImClone Investigational Site
Jacksonville, Florida, United States
ImClone Investigational Site
Miami, Florida, United States
ImClone Investigational Site
Orlando, Florida, United States
ImClone Investigational Site
Atlanta, Georgia, United States
ImClone Investigational Site
Decatur, Illinois, United States
ImClone Investigational Site
Louisville, Kentucky, United States
ImClone Investigational Site
New Orleans, Louisiana, United States
ImClone Investigational Site
Baltimore, Maryland, United States
ImClone Investigational Site
Ypsilanti, Michigan, United States
ImClone Investigational Site
Minneapolis, Minnesota, United States
ImClone Investigational Site
Saint Charles, Missouri, United States
ImClone Investigational Site
Great Falls, Montana, United States
ImClone Investigational Site
Las Vegas, Nevada, United States
ImClone Investigational Site
Voorhees Township, New Jersey, United States
ImClone Investigational Site
East Setauket, New York, United States
ImClone Investigational Site
Latham, New York, United States
ImClone Investigational Site
New York, New York, United States
ImClone Investigational Site
Cleveland, Ohio, United States
ImClone Investigational Site
Portland, Oregon, United States
ImClone Investigational Site
Greenville, South Carolina, United States
ImClone Investigational Site
Memphis, Tennessee, United States
ImClone Investigational Site
Dallas, Texas, United States
ImClone Investigational Site
Norfolk, Virginia, United States
ImClone Investigational Site
Green Bay, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA225-041
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.